Ketamine

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

Retrieved on: 
Tuesday, December 19, 2023
Psychiatry, ECT, BMJ, Partnership, American Journal, Depression, FDA, Ketamine, NDA, Hospital, Literature, Medical journal, Columbia University, Suicidal ideation, The BMJ, Dark Enlightenment, SSI, Patient, Suicide, Pharmaceutical industry

This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication.

Key Points: 
  • This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication.
  • These data mirror the results recently reported by a French consortium of hospitals who tested ketamine vs. placebo in acutely suicidal patients.
  • NRx established a similar data licensing agreement in September, 2023 ( NRx Ketamine Data Sharing, France ).
  • This filing will include manufacturing and stability data from the Company's partnership with Nephron Pharmaceuticals (West Columbia, SC).

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Retrieved on: 
Monday, November 13, 2023
Safety, Incidence, Grammatical mood, Dissociative, Plasma, Headache, Patient, Male, FDA, Treatment-resistant depression, MADRS, TRD, Czech Republic, Esketamine, Ketamine, Dizziness, Pharmaceutical industry, Dietary supplement, Boston

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its head-to-head trial with KET01, the Company’s proprietary lead asset, versus SPRAVATO®, the FDA-approved intranasal spray for patients with Treatment-Resistant Depression (TRD). KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD. Due to its unique metabolite profile, the incidence of dissociation with KET01 was very low and statistically significantly lower relative to SPRAVATO®, pointing to a clinically meaningful difference, which could offer the potential for a safe at-home unsupervised administration. During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD. 

Key Points: 
  • KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD.
  • During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD.
  • Only minimal signs of dissociative symptoms were detected by the CADSS scale, and no changes in cardiovascular parameters were detected.
  • “Data continues to suggest rapid and clinically relevant reduction of depressive symptoms after oral treatment with 240 mg/day of KET01.

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

Retrieved on: 
Wednesday, December 13, 2023
Science, Neurology, Research, Pharmaceutical, General Health, Health, Mental Health, Clinical Trials, Psilocybin, Cocaine, ATDP, Safety, Annual general meeting, Depression, Therapy, MDMA, DSM-IV codes, Patient, American College, Adderall, American College of Neuropsychopharmacology, Suds, Coronavirus Scientific Advisory Board, Ibogaine, NIH, Growth, Drug, Doctor of Philosophy, Psychiatry, Addiction, Bangladesh Technical Education Board, Ketamine, Pharmaceutical industry

DLX-007 is a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.

Key Points: 
  • DLX-007 is a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.
  • "With nearly 110,000 people dying from drug overdoses in America last year, substance use disorders remain a critical public health issue with limited treatment options.
  • Preliminary data are being generated for its potential efficacy in treating substance use disorders with cocaine, amphetamines, and multiple substances.
  • Delix is rapidly advancing its library of thousands of novel compounds into scalable, orally-bioavailable, take-home therapies.

TEGNA Names Brian Gregory President and General Manager at WVEC in Norfolk

Retrieved on: 
Monday, December 11, 2023
Communications, Media, Entertainment, TV and Radio, Other Communications, NYSE, TGNA, Newsroom, WVEC, IA Financial Group, Breaking news, WVEC-TV, Multimedia, WJET, Communication, News, TEGNA, Pennsylvania State University, KDVR, KOVR, KWCH, WVLT, Management, Hampton Roads, Ketamine

TEGNA Inc. (NYSE: TGNA) today announced that Brian Gregory has been named president and general manager at WVEC, TEGNA’s ABC affiliate serving the Hampton Roads region of Virginia and northeastern North Carolina, effective December 18.

Key Points: 
  • TEGNA Inc. (NYSE: TGNA) today announced that Brian Gregory has been named president and general manager at WVEC, TEGNA’s ABC affiliate serving the Hampton Roads region of Virginia and northeastern North Carolina, effective December 18.
  • Gregory will be responsible for overseeing the station’s operations across all platforms, as well as community outreach efforts and driving results for advertisers.
  • “Brian brings a proven track record of performance to his new position at WVEC,” said Paul Trelstad, senior vice president, media operations, TEGNA.
  • He’ll be an excellent addition to our strong, capable team in Norfolk.”
    Added Gregory, “It is a tremendous honor to join the WVEC team.

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Pharmaceutical, General Health, Health, Mental Health, Genetics, Clinical Trials, Other Health, CNS, Psilocybin, Bowdle, South Dakota, DMT, Phase 1, Therapy, DSM-IV codes, Prefrontal cortex, Plasma, Food, CSF, SAD, Hallucination, Patient, Memantine, Neuron, American College, Pharmacokinetics, Science, Cardiotoxicity, Mysticism, MD, Drug discovery, Psychiatry, Coronavirus Scientific Advisory Board, Ketamine, Drug development, Traffic barrier, Pharmaceutical industry, Generic drug, Vaccine, Medical imaging, Ramipril, Allopregnanolone, Safety

Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.

Key Points: 
  • Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.
  • “Delix is excited to share these data from DLX-001, the first novel neuroplastogen to enter clinical testing.
  • These data reinforce the potential of our broader neuroplastogen platform to develop therapies that can repair damaged neurons,” said Delix CEO Mark Rus.
  • I look forward to leveraging his considerable experiences as we progress our novel neuroplastogen platform and build Delix into a leading neuroscience company."

Ketamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Hospitals, Other Health, Other Travel, Health, Pharmaceutical, General Health, Destinations, Travel, Pain, Tennis elbow, OCD, PRP, Depression, History, Chronic pain, Patient, DSM-IV codes, Incidence, PTSD, Nursing, Ketamine

Nagoya Anesthesia Clinic ( https://nagoyamasui.com/2-2 ), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine.

Key Points: 
  • Nagoya Anesthesia Clinic ( https://nagoyamasui.com/2-2 ), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine.
  • Over the past 15 years, the clinic has provided ketamine therapy through more than 1300 ketamine infusions.
  • Drawing on their extensive experience of performing Ketamine infusions for various pain and mental disorders, Nagoya Anesthesia Clinic has established the Ketamine Clinic based on Ketamine's potent analgesic and antidepressant properties.
  • Nagoya Anesthesia Clinic "Ketamine Clinic" Information Page:

The Ketamine Healing Clinic Announces their At-Home Depression, Anxiety & Chronic Pain Ketamine Program- Nutrabrain™

Retrieved on: 
Wednesday, December 13, 2023
UCLA, USC, Depression, Chronic pain, Medical director, Chicago Medical School, Migraine, Patient, Multimedia, Pharmacy, LOS, University, Ketamine, Anxiety, MD, PTSD, Mental health, Alcoholism, University of Southern California, Neuropathic pain, Arthritis, Medical device, Hospital

LOS ANGELES, Dec. 13, 2023 /PRNewswire-PRWeb/ -- The Ketamine Healing Clinic of Los Angeles and Orange County, known worldwide for its pioneering work in ketamine therapy, is proud to announce its latest offering: the at-home Nutrabrain program. This innovative protocol sets a new standard in ketamine therapy, providing patients with a comprehensive and accessible solution for mental health, chronic pain, and alcoholism needs. Dr. David Mahjoubi, MD, the esteemed Medical Director of the Ketamine Healing Clinic, has long been recognized as a trailblazer in the field of ketamine treatment. With the introduction of the Nutrabrain program, Dr. Mahjoubi aims to revolutionize the way patients receive and benefit from ketamine therapy. The Nutrabrain protocol offers patients a seamless and effective treatment journey. First, patients will need to complete a video consultation with Dr. David Mahjoubi, MD, to determine the most suitable treatment plan. After the prescription is electronically wired to the pharmacy, the Ketamine is sent to the patient, ensuring a hassle-free experience. This supply will last for two treatments per week over four weeks, constituting the Nutrabrain protocol. If patients wish to continue the treatment, they can schedule another video consultation with Dr. David Mahjoubi and receive another one-month supply. This step can be repeated three times, after which patients qualify for a 90-day prescription supply. A minimum of four weeks between consultations is required. The protocol and 3-month prescription can allow for continued treatment and sustained relief, in the comfort of one's home, from a range of conditions, including anxiety, depression, PTSD, chronic pain, psychiatric medication tapering, migraines, neuropathic pain and arthritic pain. The Ketamine Healing Clinic of Los Angeles and Orange County is at the forefront of this innovative treatment approach, providing a safe and convenient way for patients to undergo transformative therapy. With a team of highly skilled professionals, the clinic is committed to delivering personalized care and achieving optimal outcomes for every individual. To learn more about the Nutrabrain protocol and start a journey towards improved mental health, please visit http://www.ketaminehealing.com/at-home-ketamine/.

Key Points: 
  • Dr. David Mahjoubi, MD, the esteemed Medical Director of the Ketamine Healing Clinic, has long been recognized as a trailblazer in the field of ketamine treatment.
  • Dr. Mahjoubi founded The Ketamine Healing Clinic of Los Angeles in 2014, making him one of the longest-running Ketamine clinics in the world.
  • For information on the Ketamine Healing Clinic of Los Angeles and the Ketamine Healing Clinic of Orange County please visit the website at http://www.ketaminehealing.com , or call (424) 278-4241 or (949) 514-8261.
  • Dr. David Mahjoubi, Ketamine Healing Clinic of Los Angeles & Orange County, (424) 278-4241, [email protected] , https://www.ketaminehealing.com/
    View original content to download multimedia: https://www.prweb.com/releases/the-ketamine-healing-clinic-announces-the...

NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event

Retrieved on: 
Monday, December 11, 2023
Therapy, Dark Enlightenment, Urine, Pain, GMP, HOPE, Beacon Grand Hotel, Comment, IND, DCS, Patient, Alvogen, FDA, DSM-IV codes, Cyclothymia, Conference, NIH, Low back pain, HEAL, Powell Street, Chronic pain, Ketamine, Bipolar, Pharmaceutical industry

RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Key Points: 
  • RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.
  • NRx currently has four (4) near-term shots on goal with meaningful commercial and/or monetization opportunities:
    NRX-100 – Intravenous Ketamine.
  • NRx will be hosting 1x1 meetings at the Beacon Grand Hotel (450 Powell Street, a block away from the JP Morgan Conference at Union Square).
  • To schedule a meeting, please register at LifeSci Partners Corporate Access Event 2024 and request a meeting with management.

Cordance Medical Announces Agreement with Stanford Medicine's Airan and Williams Labs for Precision Neuropsychiatry with Ultrasonic Drug Uncaging Technology

Retrieved on: 
Thursday, December 7, 2023
DRS, Neuropsychiatry, Brain, Airan, Research, Associate professor, Chronic pain, Psychiatry, Assistant professor, Nanoparticle, Patient, Medicine, Neurology, BBB, Neuro, Pi, Ketamine, Health, Diffusion, Traffic barrier, Medical imaging, Cordance

MOUNTAIN VIEW, Calif., Dec. 7, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical technology company focused on non-invasive brain treatments, is pleased to announce a new strategic agreement with Stanford Medicine, working with radiologist Dr. Raag Airan, Assistant Professor, and neurologist-psychiatrist Dr. Nolan Williams, Associate Professor, Stanford Medicine. This collaboration will combine Cordance's breakthrough NeuroAccess™ device with Dr. Airan's novel nanoparticle drug development to establish a new standard for precision medicine in neurology and psychiatry. Dr. Airan is also an Advisor with Cordance Medical.

Key Points: 
  • The combined expertise of Cordance and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
  • This method enables focal noninvasive drug delivery with the Airan Lab's pioneering technology of Ultrasonic Drug Uncaging, leveraging the capabilities of NeuroAccess beyond its original function of blood-brain barrier (BBB) opening.
  • "With this agreement, we're taking a critical step forward in the field of precision neuropsychiatry," said Ryan Dittamore, CEO of Cordance.
  • Airan and Williams at Stanford Medicine said, "Our labs have made significant strides in developing ultrasonic drug uncaging using drug-loaded nanoparticles that can be triggered using short, low-intensity ultrasound pulses.

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Retrieved on: 
Wednesday, November 29, 2023
Absorption, Caco-2, Depression, Research, Safety, Hope, MIRA, Projection, DSM-IV codes, IQVIA, Patient, Esketamine, MBBS, MD, TRD, Drug development, Drug, Suicidal ideation, Mouth, MDSI, Pharmaceutical industry, Ketamine

BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.

Key Points: 
  • BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.
  • Given oral Ketamine's previously determined 23% bioavailability when taken by mouth, Ketamir-2's adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1.
  • "This positive financial outlook bolsters our confidence in advancing Ketamir-2's clinical development," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals.
  • This advancement is not just a milestone for MIRA Pharmaceuticals, but a beacon of hope for millions battling severe depression."